Profile data is unavailable for this security.
About the company
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
- Revenue in USD (TTM)57.53m
- Net income in USD-19.99m
- Incorporated2006
- Employees109.00
- LocationPrecision BioSciences Inc302 E Pettigrew St Ste A100DURHAM 27701-2393United StatesUSA
- Phone+1 (919) 314-5512
- Fax+1 (480) 393-5553
- Websitehttps://precisionbiosciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimerix Inc | 41.00k | -82.59m | 83.85m | 72.00 | -- | 0.4816 | -- | 2,045.09 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| IO Biotech Inc | 0.00 | -88.50m | 84.99m | 68.00 | -- | 0.736 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Allovir Inc | 0.00 | -179.53m | 86.83m | 112.00 | -- | 0.7202 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 86.86m | 231.00 | -- | 5.62 | -- | 5.55 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Leap Therapeutics Inc | 0.00 | -53.37m | 87.24m | 54.00 | -- | 1.23 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Precision BioSciences Inc | 57.53m | -19.99m | 87.61m | 109.00 | -- | 2.35 | -- | 1.52 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 87.88m | 47.00 | -- | 2.20 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 88.13m | 25.00 | -- | 3.05 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 89.01m | 20.00 | -- | 1.24 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 89.16m | 29.00 | 1.17 | 1.20 | -- | 0.6351 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 89.38m | 15.00 | 8.84 | 0.5349 | 8.56 | 132.62 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 89.75m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 31 Mar 2024 | 589.57k | 8.52% |
| Janus Henderson Investors US LLCas of 08 Apr 2024 | 511.11k | 7.39% |
| Perceptive Advisors LLCas of 08 Apr 2024 | 500.00k | 7.23% |
| Aquilo Capital Management LLCas of 08 Apr 2024 | 385.44k | 5.57% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 260.83k | 3.77% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 250.00k | 3.62% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 114.27k | 1.65% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 99.50k | 1.44% |
| Citadel Advisors LLCas of 31 Mar 2024 | 97.28k | 1.41% |
| Moloney Securities Asset Management LLCas of 31 Mar 2024 | 54.20k | 0.78% |
